Latest From Vtesse Inc.
Biopharma financing finished off 2017 strong with a total value of $14.5 billion in Q4, led again by FOPOs. CVS' massive $77 billion acquisition of Aetna resulted in an all-time quarterly high in the M&A category, and the largest alliances were dominated by the development of vaccines and antibodies.
Mallinckrodt is to acquire Sucampo Pharmaceuticals for about $1.2bn. The deal brings it a short-term sales boost from Amitiza, although the constipation treatment only has a few years left before generic competition hits. Longer-term hopes lie in two Phase III products for rare diseases.
Start-up Impact's new structured financing – its second fundraising event this month – will pay out in increments as fedratinib nears the market. Also, Ablynx closed its $200m US IPO; Chi-Med follow-on brings in $262m; and VCs gives Cydan $34m to launch new companies.
A review of biopharma start-up dealmaking and financing activity from April through June 2017, based on data from Strategic Transactions, showed that fundraising activity more than doubled compared with the first quarter.
- Therapeutic Areas
- Metabolic Disorders
- Neurology, Nervous System
- North America
- Company Type
- Parent & Subsidiaries
- Vtesse Inc.
- Senior Management
Ben Machielse, Pres. & CEO
Ravi Rao, PhD, CBO
Michael Massaro, VP, Clinical Operations
Kevin B Johnson, PhD, VP, Regulatory Affairs
Jason Meyenburg, Chief Commercial Officer
Allan Darling, PhD, VP, Tech. Operations
- Contact Info
Phone: (240) 801-9261
910 Clopper Rd.
Suite 220 S
Gaithersburg, MD 20878
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.